news
New small molecule blocks immune response signalling pathway
A new small molecule has great promise for the treatment of autoimmune diseases by inhibiting the proinflammatory signalling pathway.
List view / Grid view
University of Lausanne
news
New cell discovery shakes up neuroscience
Scientists have identified a novel cell type that combines astrocytic characteristics with the machinery for synaptic transmission. This discovery resolves years of debate in the field.
news
Researchers reveal frameshifting as SARS-CoV-2 drug target
A critical stage of the SARS-CoV-2 replication process, known as frameshifting, could be targeted by new drugs, researchers say.
news
Blocking bacterial competence could prevent antibiotic resistance
Scientists suggest competence-blocking, ‘anti-evolution’ drugs could be administered alongside antibiotics to prolong the period before bacterial resistance emerges.
news
Disrupting macrophage action aids melanoma immunotherapy success
Scientists in Switzerland have uncovered a potential means of increasing effective treatment of melanomas with immunotherapy, by disrupting the action of macrophages.
news
From cancer evolution to personalised therapies
A research team have studied how alterations in a tumour depend on each other and how these dependencies determine cancer evolution...
news
MRC Technology & University of Lausanne collaborate on MALT1 inhibitors
24 September 2015 | By Victoria White
Disregulation of MALT1 is associated with some subsets of lymphoma suggesting that MALT1 could be a promising drug target for these types of cancer...
